2019 Outlook and Objectives

2019 Outlook

 
MDKK

Revenue

Operating expenses

Operating income

2019
Guidance

4,600

(2,600)

2,000

2018
Actual Result

3,025

(1,645)

1,380

Key 2019 Priorities

Daratumumab
  • FDA decision on Phase III MAIA multiple myeloma (MM) submission
  • FDA decision on Phase III CASSIOPEIA MM submission
  • Phase III COLUMBA MM subcutaneous (SC) daratumumab safety and efficacy analysis
Ofatumumab
  • Phase III ASCLEPIOS I & II relapsing multiple sclerosis SC ofatumumab study completion and reporting
Tisotumab Vedotin
  • Phase II tisotumab vedotin recurrent/metastatic cervical cancer study enrollment complete by mid year
Innovative Pipeline
  • Phase II enapotomab vedotin expansion cohort efficacy analysis
  • Phase I/II HexaBody-DR5/DR5 initial clinical data
  • Phase I/II DuoBody CD3xCD20 clinical data dose escalation cohorts
  • File INDs or CTAs for 3 new products